Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Hepatitis B vaccine protection is considered long lasting, likely for at least 30 years and possibly for life in healthy people who completed the full series, so routine boosters are not recommended for most adults. Titer testing (anti-HBs antibody levels) is advised for specific groups, including healthcare and public safety workers with blood exposure, infants born to HBsAg-positive mothers, people on dialysis, those who are immunocompromised, and sexual partners or household contacts of someone with chronic hepatitis B. Timing, the 10 mIU/mL threshold, and what to do about a non-response or waning antibodies all matter, and there are several important factors to consider, so see below to understand more before assuming you are protected or unprotected.
If you are unsure about your immunity, have had a possible exposure, or are noticing symptoms such as fatigue, nausea, dark urine, abdominal discomfort, or yellowing of the eyes or skin, getting clarity quickly can change what you do next. Take a free, instant, online symptom check to better understand what may be going on and which type of care or testing to pursue.
Last reviewed for medical accuracy: 10/01/2025
Hepatitis B is a liver infection caused by the hepatitis B virus (HBV). Vaccination is the most effective way to prevent infection. Many people wonder: how long does hepatitis B vaccine last? Here’s what current research and expert guidelines tell us, plus who should check their antibody levels (titers).
Strong, lasting immunity
After completing the standard 3-dose series, 90–95% of healthy adults develop protective antibody levels (anti-HBs ≥10 mIU/mL). Studies show:
Factors that may affect duration
While most maintain immunity for decades, some groups may lose protection faster:
A titer check measures anti-HBs levels to confirm protection. It’s not required for everyone—only certain groups at higher risk of exposure or with weakened immune systems.
Timing
Blood test
Interpreting results
Current U.S. and World Health Organization (WHO) guidelines agree:
Understanding your level of protection can ease anxiety. If you have any signs of hepatitis (e.g., fatigue, jaundice, abdominal pain), don’t ignore them. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help assess your situation.
Always follow up with your healthcare provider for testing, vaccination, or any treatment.
If you have questions about your hepatitis B immunity or any serious symptoms, speak to a doctor for personalized advice—especially if you develop signs of liver injury or feel unwell.
(References)
* Sasagawa N, Ozaki K, Matsuzaki S. Change in antibody titer 3 years after inoculation with recombinant hepatitis B vaccine. Tokai J Exp Clin Med. 1992 Dec;17(5-6):179-86. PMID: 1343425.
* Kaur H, Kumar R, Marshalla R. Seroconversion and seroprotection following hepatitis B vaccination. Indian J Gastroenterol. 1998 Jan;17(1):36. PMID: 9465521.
* Kaur H, Mani A. Seroprotection following Enivac-HB, a recombinant hepatitis B vaccine. Indian J Gastroenterol. 2000 Jan-Mar;19(1):41. PMID: 10659495.
* Duval B, Deceuninck G. Seroprotection rates after late doses of hepatitis B vaccine. Pediatrics. 2002 Feb;109(2):350-1. doi: 10.1542/peds.109.2.350. PMID: 11826227.
* Velu V, Nandakumar S, Shanmugam S, Thyagarajan SP. Persistence of anti-HBs titers after two different doses of Genevac B, a recombinant hepatitis B vaccine, in healthy adolescents. Indian J Gastroenterol. 2007 Jan-Feb;26(1):48. PMID: 17401247.
* Bloom A, Jackson K, Kiviat A, Zheng H, Sax P, Gandhi R. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):110-3. doi: 10.1097/QAI.0b013e318183acc0. PMID: 19092450.
* Lee GH, Lim SG. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. Expert Rev Vaccines. 2021 May;20(5):487-495. doi: 10.1080/14760584.2021.1908133. Epub 2021 Apr 9. PMID: 33783302.
* Awad AM, Ntoso A, Connaire JJ, Hernandez GT, Dhillon K, Rich L, Henderson H, Lynn R, Hyer RN, Xie F, Erby K, Janssen RS, HBV-24 Study Group. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. Vaccine. 2021 Jun 8;39(25):3346-3352. doi: 10.1016/j.vaccine.2021.05.003. Epub 2021 May 14. PMID: 34001345.
* Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine. 2021 Jun 29;39(29):3892-3899. doi: 10.1016/j.vaccine.2021.05.067. Epub 2021 Jun 8. PMID: 34116873.
* Mo X, Men Z, Gao L, Gao Y, Yao T, Liu Y, Yuan Y, Xue T, Wang F, Wang S, Wang K, Liang X, Feng Y. Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China. Hum Vaccin Immunother. 2025 Dec;21(1):2447108. doi: 10.1080/21645515.2024.2447108. Epub 2025 Jan 17. PMID: 39819251; PMCID: PMC12934167.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.